Asia pacific nuclear medicine radiopharmaceuticals stable isotopes

2018 asia-pacific nuclear medicine/radiopharmaceuticals & stable isotopes market john brown nuclear medicine - thyroid - an example of the process - duration: 8:54. Investments on discovery new radioisotopes and the use of radiopharmaceuticals and stable isotopes novel applications such as neurological applications are the winning imperatives adopted by market players to gain a stronghold of the market.

Similar to the global nuclear medicine market, the asia-pacific region is also reducing its dependency on nuclear reactors by introducing hospital-based cyclotron facilities this paves the way for novel isotopes such as tl-201, f-18, and rb-82 to capitalise on opportunities in the growing diagnostics market. Radiopharmaceuticals in neurological applications such as alzheimer's disease, parkinson's disease, and dementia are boosting the growth of the asia-pacific nuclear medicine market upcoming radioisotopes such as ra-223 (alpharadin) and ga-68 possess huge potential for clinical applications.

The asia-pacific radiopharmaceutical market was valued at $5008 million in 2012 and is poised to reach $8249 million by 2017 at a compound annual growth rate (cagr) of 105 percent, according to a report from markets and markets. The asia-pacific stable isotopes market is dominated by deuterium (d2), oxygen-18 (o-18), carbon-13 (c-13), and nitrogen-15 (n-15) research, pharmaceuticals, diagnostic and therapy, and industries are major applications.

2018 asia-pacific nuclear medicine/radiopharmaceuticals & stable isotopes market john brown nuclear medicine - thyroid - an example of. Further, the asia-pacific nuclear medicine/radiopharmaceuticals & stable isotopes market research report study also encompasses complete industry background, with asia-pacific nuclear medicine/radiopharmaceuticals & stable isotopes market drivers, competitive market dynamics, market restraints, market growth opportunities, industry challenges and critical success factors (csfs. Asia-pacific nuclear medicine/radiopharmaceuticals & stable isotopes market research report - forecast to 2017.

Asia-pacific has the largest share in terms of r&d investment is driving the market for stable isotope, but the high cost of stable isotopes is hampering the market in this region. Iq4i research & consultancy published a new report on nuclear medicine/ radiopharmaceuticals global market-forecast to 2024 this report analyzes and studies the overall market, major drivers & opportunities, restraints & threats in north america, europe, asia-pacific and rest of the world. The asia-pacific nuclear medicine/radiopharmaceuticals market & stable isotopes [spect/pet radioisotopes (technetium, f-18)], [beta/alpha radiation therapy (i131, y-90)], [applications (cancer/oncology, cardiac)] & (deuterium, c-13) - forecast to 2017 looks at the major market drivers, restraints, and opportunities in japan, china, india, south korea, indonesia, malaysia, australia, new zealand, and rest of asia. Asia-pacific nuclear medicine/radiopharmaceutical market worth $825 million by 2017 [313 report pages] the asia-pacific nuclear medicine/radiopharmaceuticals & stable isotopes market have been segmented according to the type of isotope, and applications.

Asia pacific nuclear medicine radiopharmaceuticals stable isotopes

Asia pacific nuclear medicine/radiopharmaceuticals & stable isotopes market - opportunities and forecasts, 2017-2023. Nuclear medicine global market is expected to reach $9,3678 million by 2024 at a cagr of 65% stable isotope global market is expected to reach $2569 million by 2024 at a cagr of 28% identification and analysis of the nuclear medicine global market segments by modality, products, by application, end-user and geography.

Radiopharmaceuticals in neurological applications such as alzheimer’s disease, parkinson’s disease, and dementia are boosting the growth of the asia-pacific nuclear medicine market upcoming radioisotopes such as ra-223 (alpharadin) and ga-68 possess huge potential for clinical applications.

asia pacific nuclear medicine radiopharmaceuticals stable isotopes Radiopharmaceuticals are used in the field of nuclear medicine as tracers in the diagnosis and treatment of many diseases utilization of these molecules for medical purposes in pet and spect imaging has changed the entire algorithm of disease diagnosis. asia pacific nuclear medicine radiopharmaceuticals stable isotopes Radiopharmaceuticals are used in the field of nuclear medicine as tracers in the diagnosis and treatment of many diseases utilization of these molecules for medical purposes in pet and spect imaging has changed the entire algorithm of disease diagnosis.
Asia pacific nuclear medicine radiopharmaceuticals stable isotopes
Rated 4/5 based on 41 review
Download